Back to search results

Virtual Reality (VR)-Directed Brain Gut Behavioral Treatment (BGBT) for IBD Inpatients

This study is exploring a new way to help hospitalized patients with Inflammatory Bowel Disease (IBD) manage their pain. Researchers are testing a treatment called virtual reality (VR)-directed Brain Gut Behavioral Treatment (BGBT). This involves using VR for activities like distraction games, mindfulness, breathing exercises, and coaching based on cognitive behavioral therapy. The main goal is to see if this VR-directed BGBT program is practical and acceptable for patients to complete during their hospital stay. You might be able to join if you are an adult with IBD, are currently hospitalized at Michigan Medicine for IBD, and are experiencing pain. The study aims to enroll 40 participants and will measure if at least 75% of participants complete the 3-day VR program.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It aims to enroll 40 participants.
What's involved
Participants will receive up to 3 days of VR-directed BGBT through various modules.
Compensation
Not stated in the trial record.
Follow-up
Feasibility is measured at 3 days of treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06188793

Virtual Reality (VR) -Directed Brain Gut Behavioral Treatment (BGBT) for Inflammatory Bowel Disease (IBD) Inpatients

Recruiting
NAAges 18+InterventionalTreatment
University of Michigan
~40 participants
Updated 2026-07-23 on ClinicalTrials.gov
What's tested:Virtual reality-directed BGBT

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Feasibility of the intervention measured as the frequency (percentage) of enrolled participants that complete the VR-directed BGBT inpatient program
Measured over 3 days of treatment

Conditions

Inflammatory Bowel Diseases

Explore related trials

Inflammatory Bowel Disease

Where it's being run

1 sites across 1 states
Michigan1

Study leadership

  • Shirley Cohen-Mekelburg, MD, MS · PRINCIPAL_INVESTIGATOR · University of Michigan

Who to contact

Shirley Cohen-Mekelburg, MD, MS
[email protected]
734-845-5735
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients with Inflammatory Bowel Disease and self-reported pain
Hospitalized for management of IBD (inpatient medicine services at Michigan Medicine)

Exclusion

Patients that do not report pain
Anticipated length of hospital stay is less than 72 hours
Patients that have previously had a seizure, loss of awareness, or other symptoms linked to an epileptic condition
Patients with binocular vision loss
Patients with an uncontrolled cardiac condition such as an arrhythmia, coronary artery disease, or neurological/cerebrovascular disease.
Patients that are currently pregnant

What this trial measures

  • Feasibility of the intervention measured as the frequency (percentage) of enrolled participants that complete the VR-directed BGBT inpatient program3 days of treatment